SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002; 10: 8189.
  • 2
    DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231: 5158.
  • 3
    Nilsson B, Beumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer. 2005; 103: 821829.
  • 4
    Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003; 98: 26932699.
  • 5
    Patel S, Vadhan-Raj S, Papadopoulos N, et al. High-dose Ifosfamide in bone and soft-tissue sarcomas — results of phase II and pilot studies — dose response and schedule dependence. J Clin Oncol. 1997; 15: 23782384.
  • 6
    Patel S, Vadhan-Raj S, Burgess M, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998; 21: 317321.
  • 7
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472480.
  • 8
    Rankin C, von Mehren M, Blanke CD, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST — Phase III Sarcoma Group Study S0033. Am Soc Clin Oncol. 2004; 23: 815. Abstract 9005.
  • 9
    Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 11271134.
  • 10
    Van den Abbeele A, Badawi R, Cliche J-P, et al. 18F-FDG PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2002; 21: 403a. Abstract 1610.
  • 11
    Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004; 183: 16191628.
  • 12
    Choi H, Charnsangavej C, Macapinlac H, et al. Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate. Am Soc Clin Oncol. 2003; 22: 819. Abstract 3290.
  • 13
    Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005; 16: 566578.
  • 14
    Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004; 363: 13461353.
  • 15
    Schedlich LJ, Graham LD. Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech. 2002; 59: 1222.
  • 16
    Schedlich LJ, O'Han MK, Leong GM, Baxter RC. Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells. Biochem Biophys Res Commun. 2004; 314: 8388.
  • 17
    Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001; 20: 50545058.
  • 18
    Wang G, Kong H, Sun Y, et al. Genome-wide analysis of the cyclin family in Arabidopsis and comparative phylogenetic analysis of plant cyclin-like proteins. Plant Physiol. 2004; 135: 10841099.
  • 19
    Shmulevich I, Hunt K, El-Naggar A, et al. Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity. Cancer. 2002; 94: 20692075.
  • 20
    Baggerly KA, Coombes KR, Hess KR, et al. Identifying differentially expressed genes in cDNA microarray experiments. J Comput Biol. 2001; 8: 639659.
  • 21
    Trent JC2nd, McConkey DJ, Loughlin SM, Harbison MT, Fernandez A, Ananthaswamy HN. Ras signaling in tumor necrosis factor-induced apoptosis. EMBO J. 1996; 15: 44974505.
  • 22
    Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005; 16: 11601168.
  • 23
    Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001; 115: 793800.
  • 24
    Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thoracic Surg. 2004; 78: 11521160; discussion 1152–1160.
  • 25
    Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics. 2005; 25: 191207.
  • 26
    Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999; 84: 22912302.
  • 27
    Subramanian S, West RB, Corless CL, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene. 2004; 23: 77807790.
  • 28
    Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther. 2003; 2: 699709.
  • 29
    Baxter RC, Butt AJ, Schedlich LJ, Martin JL. Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3. Growth Horm IGF Res. 2000; 10: S1011.
  • 30
    Brodt P, Samani A, Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol. 2000; 60: 11011107.
  • 31
    Mauro L, Salerno M, Morelli C, Boterberg T, Bracke ME, Surmacz E. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J Cell Physiol. 2003; 194: 108116.
  • 32
    Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene. 2003; 22: 974982.
  • 33
    Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer. 2004; 90: 18251829.
  • 34
    Lee HY, Moon H, Chun KH, et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst. 2004; 96: 15361548.
  • 35
    Oesterreicher S, Blum WF, Schmidt B, Braulke T, Keubler B. Interaction of insulin-like growth factor II (IGF-II) with multiple plasma proteins: high affinity binding of plasminogen to IGF-II and IGF-binding protein-3. J Biol Chem. 2005; 280: 999410000.
  • 36
    Sebastian S, Kenkare UW. Stimulation of brain hexokinase gene expression by recombinant brain insulin-like growth factor in C6 glial cells. Exp Cell Res. 1999; 246: 243247.